Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gedatolisib in HR+/HER2- Advanced Breast Cancer (VIKTORIA-1)
NCT05501886Phase 3Active, not recruiting
- Sponsor
- Celcuity Inc.
- Start
- Dec 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of gedatolisib in Hormone-Receptor-Positive Breast Cancer, sponsored by Celcuity Inc.. Started Dec 2022; status: active, not recruiting.
02
Drugs
gedatolisib
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT05501886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05501886.